NETRAMARK HOLDINGS INC.

Highlights NetraMark Holdings Inc. Canadian Securities Exchange

Stocks

AIAI

CA64119M1059

Software

End-of-day quote Canadian Securities Exchange 2026-02-20			5-day change	1st Jan Change
1.070 ^CAD	-.--%		-3.77%	-7.27%

09-10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
09-01	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI

Highlights

09-10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
08-14	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-09	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT
07-09	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	CI
06-29	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
06-29	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
05-14	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-22	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	CI
04-20	NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics	CI
04-09	Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes	CI
03-25	NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset	MT
03-25	Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration	CI
03-25	NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	MT
03-19	NetraMark Holdings Inc Unveils Ai-Discovered Treatment-Responsive Subgroups In A4 Alzheimer?s Trial	CI
03-11	NetraMark Signs Contract With Global Biopharmaceutical Company	CI
03-11	NetraMark Signs Contract With Biopharma Company to Analyze Phase 2 Trial Data	MT

No results match your criteria

All News Broker Recommendations Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

-40%: Exceptional extension

SEIZE THE OFFER!